(DGX) Quest Diagnostics - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 20.657m USD | Total Return: 10.7% in 12m
Clinical Testing, Anatomic Pathology, Diagnostic Information, Health IT
Total Rating 70
Safety 96
Buy Signal 0.07
Diagnostics & Research
Industry Rotation: +6.8
Industry Rotation: +6.8
Market Cap:
20.7B
Avg Turnover: 148M
Avg Turnover: 148M
Risk 3d forecast
Volatility22.0%
VaR 5th Pctl3.46%
VaR vs Median-4.60%
Reward TTM
Sharpe Ratio0.37
Rel. Str. IBD39.5
Rel. Str. Peer Group44.6
Character TTM
Beta0.126
Beta Downside0.082
Hurst Exponent0.487
Drawdowns 3y
Max DD16.57%
CAGR/Max DD0.97
CAGR/Mean DD3.33
EPS (Earnings per Share)
EPS CAGR: 6.05%
EPS Trend: 93.7%
EPS Trend: 93.7%
Last SUE: 2.53
Qual. Beats: 3
Qual. Beats: 3
Revenue
Rev. CAGR: 7.95%
Rev. Trend: 93.3%
Rev. Trend: 93.3%
Last SUE: 2.52
Qual. Beats: 4
Qual. Beats: 4
Warnings
Choppy
Tailwinds
No distinct edge detected
Description: DGX Quest Diagnostics
Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic information services, operating a vast network of laboratories and patient service centers across the United States. The company’s business model centers on high-volume clinical testing, ranging from routine blood work to advanced molecular diagnostics and anatomic pathology. By leveraging an extensive logistics infrastructure, Quest serves a diverse client base including physicians, hospitals, health plans, and life insurers.
The diagnostic testing sector is characterized by high fixed costs and significant economies of scale, where market leaders benefit from broad payer coverage and integrated healthcare IT solutions. Quest further diversifies its revenue through specialized services such as workplace drug testing, risk assessment for the insurance industry, and the development of in vitro diagnostic tests. For those evaluating the long-term fundamentals of this industry, ValueRay provides additional data points to consider. Founded in 1967 and headquartered in New Jersey, the company remains a critical component of the domestic healthcare supply chain.
- Base business volume recovery and routine testing demand drive revenue growth
- Strategic acquisitions of hospital laboratory systems expand market share and scale
- Medicare reimbursement cuts under PAMA legislation create persistent margin pressure
- Growth in advanced diagnostics and molecular testing increases average revenue per test
- Labor cost inflation and phlebotomist shortages impact operational efficiency and margins
Piotroski VR‑10 (Strict)
7.5
| Net Income: 1.02b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.27 > 1.0 |
| NWC/Revenue: 3.45% < 20% (prev 6.24%; Δ -2.79% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.85b > Net Income 1.02b |
| Net Debt (6.59b) to EBITDA (1.98b): 3.33 < 3 |
| Current Ratio: 1.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.0m) vs 12m ago -0.88% < -2% |
| Gross Margin: 33.23% > 18% (prev 0.33%; Δ 3.29k% > 0.5%) |
| Asset Turnover: 69.47% > 50% (prev 64.30%; Δ 5.16% > 0%) |
| Interest Coverage Ratio: 5.68 > 6 (EBITDA TTM 1.98b / Interest Expense TTM 265.0m) |
Altman Z''
3.94
| A: 0.02 (Total Current Assets 2.57b - Total Current Liabilities 2.18b) / Total Assets 16.67b |
| B: 0.61 (Retained Earnings 10.15b / Total Assets 16.67b) |
| C: 0.09 (EBIT TTM 1.51b / Avg Total Assets 16.23b) |
| D: 1.12 (Book Value of Equity 10.11b / Total Liabilities 9.01b) |
| Altman-Z'' Score: 3.94 = AA |
Beneish M
-3.01
| DSRI: 1.02 (Receivables 1.59b/1.40b, Revenue 11.28b/10.16b) |
| GMI: 0.99 (GM 33.23% / 32.84%) |
| AQI: 0.97 (AQ_t 0.67 / AQ_t-1 0.69) |
| SGI: 1.11 (Revenue 11.28b / 10.16b) |
| TATA: -0.05 (NI 1.02b - CFO 1.85b) / TA 16.67b) |
| Beneish M-Score: -3.01 (Cap -4..+1) = AA |
What is the price of DGX shares?
As of May 21, 2026, the stock is trading at USD 193.75 with a total of 948,572 shares traded.
Over the past week, the price has changed by +1.52%, over one month by -1.30%, over three months by -3.86% and over the past year by +10.66%.
Over the past week, the price has changed by +1.52%, over one month by -1.30%, over three months by -3.86% and over the past year by +10.66%.
Is DGX a buy, sell or hold?
Quest Diagnostics has received a consensus analysts rating of 3.89.
Therefore, it is recommended to buy DGX.
- StrongBuy: 8
- Buy: 1
- Hold: 10
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DGX price?
| Analysts Target Price | 223.3 | 15.2% |
Quest Diagnostics (DGX) - Fundamental Data Overview
as of 17 May 2026
P/E Trailing = 20.6199 P/E Forward = 17.452
P/S = 1.8316
P/B = 2.8161
P/EG = 1.4426
Revenue TTM = 11.28b USD
EBIT TTM = 1.51b USD
EBITDA TTM = 1.98b USD
Long Term Debt = 5.16b USD (from longTermDebt, last quarter)
Short Term Debt = 677.0m USD (from shortTermDebt, last quarter)
Debt = 6.98b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.59b USD (from netDebt column, last quarter)
Enterprise Value = 27.24b USD (20.66b + Debt 6.98b - CCE 393.0m)
Interest Coverage Ratio = 5.68 (Ebit TTM 1.51b / Interest Expense TTM 265.0m)
EV/FCF = 20.55x (Enterprise Value 27.24b / FCF TTM 1.33b)
FCF Yield = 4.87% (FCF TTM 1.33b / Enterprise Value 27.24b)
FCF Margin = 11.76% (FCF TTM 1.33b / Revenue TTM 11.28b)
Net Margin = 9.08% (Net Income TTM 1.02b / Revenue TTM 11.28b)
Gross Margin = 33.23% ((Revenue TTM 11.28b - Cost of Revenue TTM 7.53b) / Revenue TTM)
Gross Margin QoQ = 32.54% (prev 32.57%)
Tobins Q-Ratio = 1.63 (Enterprise Value 27.24b / Total Assets 16.67b)
Interest Expense / Debt = 0.90% (Interest Expense 63.0m / Debt 6.98b)
Taxrate = 22.16% (74.0m / 334.0m)
NOPAT = 1.17b (EBIT 1.51b * (1 - 22.16%))
Current Ratio = 1.18 (Total Current Assets 2.57b / Total Current Liabilities 2.18b)
Debt / Equity = 0.95 (Debt 6.98b / totalStockholderEquity, last quarter 7.37b)
Debt / EBITDA = 3.33 (Net Debt 6.59b / EBITDA 1.98b)
Debt / FCF = 4.97 (Net Debt 6.59b / FCF TTM 1.33b)
Total Stockholder Equity = 7.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.31% (Net Income 1.02b / Total Assets 16.67b)
RoE = 14.11% (Net Income TTM 1.02b / Total Stockholder Equity 7.26b)
RoCE = 12.13% (EBIT 1.51b / Capital Employed (Equity 7.26b + L.T.Debt 5.16b))
RoIC = 9.03% (NOPAT 1.17b / Invested Capital 12.98b)
WACC = 4.98% (E(20.66b)/V(27.64b) * Re(6.43%) + D(6.98b)/V(27.64b) * Rd(0.90%) * (1-Tc(0.22)))
Discount Rate = 6.43% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -12.17 | Cagr: -0.39%
[DCF] Terminal Value 87.17% ; FCFF base≈1.22b ; Y1≈1.33b ; Y5≈1.69b
[DCF] Fair Price = 388.6 (EV 49.60b - Net Debt 6.59b = Equity 43.02b / Shares 110.7m; r=6.0% [WACC]; 5y FCF grow 10.56% → 3.0% )
EPS Correlation: 93.68 | EPS CAGR: 6.05% | SUE: 2.53 | # QB: 3
Revenue Correlation: 93.25 | Revenue CAGR: 7.95% | SUE: 2.52 | # QB: 4
EPS current Quarter (2026-06-30): EPS=2.82 | Chg30d=-1.49% | Revisions=-50% | Analysts=14
EPS next Quarter (2026-09-30): EPS=2.80 | Chg30d=+0.13% | Revisions=-29% | Analysts=14
EPS current Year (2026-12-31): EPS=10.77 | Chg30d=+1.23% | Revisions=+80% | GrowthEPS=+9.3% | GrowthRev=+7.4%
EPS next Year (2027-12-31): EPS=11.67 | Chg30d=+1.67% | Revisions=+81% | GrowthEPS=+8.4% | GrowthRev=+4.4%
[Analyst] Revisions Ratio: +81%